Fudan University
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (850 trials with phase data)• Click on a phase to view related trials
Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
- Conditions
- FAPI PETColorectal CancerPeritoneal (Metastatic) Cancer
- Interventions
- Combination Product: Radiotherapy followed by chemotherapyDrug: Chemotherapy (control)
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT07079462
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve Blockade
- Conditions
- Intercostal Nerve BlockPulmonary VentilationAnesthesia, LocalBreast NeoplasmsSurgical Procedures, Operative
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 72
- Registration Number
- NCT07079436
Transcutaneous Electrical Nerve Stimulation in Nerve-Sparing Radical Hysterectomy: Effects on Bladder Management and Quality of Life in Cervical Cancer
- Conditions
- Cervical CancerPostoperative Bladder DysfunctionUrinary RetentionPelvic Floor Muscle WeaknessLower Urinary Tract SymptomsRecovery of Bladder FunctionImprovement in Pelvic Floor Muscle StrengthEnhancement of Quality of Life
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 78
- Registration Number
- NCT07070687
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 56
- Registration Number
- NCT07070700
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
- Conditions
- Diffuse Large B-Cell LymphomaDLBCL
- Interventions
- Drug: POLA-R-CHP
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 300
- Registration Number
- NCT07070648
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 212
- Next
News
Bio-Thera's BAT4406F Achieves Early Trial Success in Rare Neurological Disorder NMOSD
Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial.
Singlera Genomics' GutSeer Assay Achieves 81.5% Sensitivity in Detecting Early-Stage Gastrointestinal Cancers
Singlera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study in Molecular Cancer, demonstrating their GutSeer assay's ability to detect five major gastrointestinal cancers through a simple blood test.
Multimodal AI System Demonstrates Superior Survival Prediction for Hepatocellular Carcinoma Immunotherapy
A novel multimodal fusion (MMF) system combining CT imaging-based deep learning with clinical features achieved C-index values of 0.74 for overall survival and 0.69 for progression-free survival in predicting outcomes for unresectable hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Physical Activity in Childhood Linked to Better Mental Health and Cognitive Function in Adolescence
Finnish longitudinal study reveals children with higher physical fitness levels develop better cognitive abilities and experience lower rates of depression and stress as teenagers.
Phase 2 Trial Shows Promise: Serplulimab-HLX04 Combination Safe for Advanced Liver Cancer
A phase 2 trial demonstrates manageable safety profile of serplulimab combined with bevacizumab biosimilar HLX04 as first-line treatment for advanced hepatocellular carcinoma.
Mixed Results for Immunotherapy in Early Triple-Negative Breast Cancer
The NSABP B-59 trial showed that adding atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in stage II-III TNBC.
Wegovy Enters Chinese Market as Obesity Rates Rise
Wegovy, a weight-loss drug containing semaglutide, has been introduced in China, offering a new treatment option for the country's increasing obese population.